Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metformin
Phase 1CompletedDevelopment Stage
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Oct 1, 2011 → Dec 1, 2011
About Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metformin
Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metformin is a phase 1 stage product being developed by AstraZeneca for Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin. The current trial status is completed. This product is registered under clinical trial identifier NCT01441869. Target conditions include Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01441869 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin